Prelude Capital Management’s Moderna MRNA Stock Holding History

Prelude Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,095	Closed	-$209K	–	1453
2025 Q4	$209K	Buy	+7,095	New	+$193K	0.02%	1037
2021 Q2	–	Sell	-4,159	Closed	-$743K	–	1846
2021 Q1	$545K	Sell	4,159 -5,741	-58%	-$832K	0.01%	861
2020 Q4	$1.03M	Buy	9,900 +8,941	+932%	+$905K	0.03%	473
2020 Q3	$68K	Buy	+959	New	+$66.9K	﹤0.01%	1036
2020 Q1	–	Sell	-12,423	Closed	-$286K	–	1819
2019 Q4	$243K	Buy	+12,423	New	+$220K	0.01%	797
2019 Q2	–	Sell	-8,541	Closed	-$174K	–	1971
2019 Q1	$174K	Buy	8,541 +3,397	+66%	+$63K	0.01%	759
2018 Q4	$79K	Buy	+5,144	New	+$84.5K	0.01%	1002

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's MRNA Position: Q1 2026 in Review

Prelude Capital Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 7,095 shares — an estimated $209K sold.

Prelude Capital Management first reported a position in MRNA in Q4 2018 and held it in 7 quarters. The position peaked at $1.03M in Q4 2020. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Prelude Capital Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 7,095 Moderna shares in Q1 2026, an estimated $209K.
Prelude Capital Management first reported a position in Moderna in Q4 2018 and held it in 7 quarters.
Prelude Capital Management's Moderna position peaked at $1.03M in Q4 2020.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.